Haisco Pharmaceutical unlocks first restricted stock period, 1.74m shares released

Haisco Pharmaceutical Group announced that conditions for the first unlocking period of its 2024 restricted stock incentive plan have been met. The company's board of directors approved the unlocking of 1,740,000 restricted shares, representing 0.1554% of the current total share capital.

According to a legal opinion, the company achieved 2024 operating income of CNY 3.721 billion and 13 IND applications for preclinical projects, exceeding targets of CNY 3.6 billion and three IND applications. Additionally, the six core business and technical personnel participating in the incentive plan received "excellent" performance evaluations, qualifying them for the 100% unlocking ratio.

The first restricted period began on October 11, 2024, and concluded on October 10, 2025. The board also noted a price adjustment for the reserved grant from CNY 14.10 per share to CNY 13.955 per share, effective September 19, 2024, following the company's 2024 semi-annual equity distribution plan. This adjustment was within the authority granted by the shareholders' meeting.